Search
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalWhile [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens … Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended.
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt has once again been approved and should soon be available on the French and Australian market. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized … [L50642] As CXCR4 mutations have also been implicated in human immunodeficiency virus (HIV), Waldenstrom’s macroglobulinemia (WM), B-cell non-Hodgkin lymphoma, and solid tumours, including melanoma,
Synonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] The approval covers adults and pediatric patients 8 years of age and older and was based on a statistically significant reduction in daily cornstarch intake, a surrogate endpoint, with … [L64050,L64051] It is administered as a single, one-time intravenous infusion.
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.
Camazepam
go.drugbank.com/drugs/DB01489ExperimentalIllicitIn the United States camazepam is regulated as a Schedule IV controlled substance. … Similarly to other drugs in its class, it has antxiolytic, anticonvulsant, hypnotic, and skeletal muscle relaxant properties.
Sarracenia Purpurea
go.drugbank.com/drugs/DB13965ApprovedWithdrawnIt was used as an injectable pain reliever and during the 19th century, _Sarracenia purpurea_ was used as a treatment of smallpox [A32509]. … Cytoprotection in an in vitro model of diabetic neuropathy has also been studied. However, the use of Sarracenia Purpurea extracts in the clinical setting are limited.
Brilliant green cation
go.drugbank.com/drugs/DB11279ApprovedVet approvedDue to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection. … Brilliant green, or ethanaminium, is a derivative of triarylmethane dye that has been used as a dye to color silk and wool.
Categories: Compounds used in a research, industrial, or household settingSilicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or
Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & DAbarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnIt is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.